鼻用布地奈德、孟鲁司特及其联合治疗季节性过敏性鼻炎的疗效与机制比较
该单中心随机开放标签研究纳入100例季节性过敏性鼻炎患者,比较布地奈德鼻喷(256μg)、孟鲁司特(10mg)及半剂量布地奈德(128μg)联合孟鲁司特治疗14天的疗效与机制。结果显示联合治疗在鼻塞改善上显著优于单药,且FeNO下降幅度更大,整体疗效可能更优。
要点
- 半剂量布地奈德联合孟鲁司特对鼻塞的改善显著优于单药治疗。
- 联合治疗降低FeNO的幅度显著大于布地奈德或孟鲁司特单药。
- 布地奈德及联合治疗降低ECP、组胺和CysLTs的幅度显著大于孟鲁司特。
核心结论
- 半剂量布地奈德联合孟鲁司特治疗季节性过敏性鼻炎的整体疗效可能优于布地奈德或孟鲁司特单药。
研究设计与样本
- 单中心、随机、开放标签研究,纳入100例季节性过敏性鼻炎患者。
- 患者随机接受布地奈德256μg、孟鲁司特10mg或半剂量布地奈德128μg联合孟鲁司特治疗14天。
主要发现
- 所有治疗均较基线显著改善症状,但联合治疗对鼻塞的改善显著大于布地奈德或孟鲁司特单药。
- 布地奈德组和联合治疗组症状未控制患者数少于孟鲁司特组,且鼻腔容积改善程度大于孟鲁司特组。
- 联合治疗较基线降低FeNO的幅度显著大于布地奈德和孟鲁司特单药。
- 布地奈德和联合治疗降低ECP、组胺和CysLTs的幅度显著大于孟鲁司特。
- 布地奈德降低鼻黏膜Th1和Th2细胞并增加Treg细胞,孟鲁司特降低外周血Th1细胞并增加Treg细胞,联合治疗反映此趋势。
临床怎么用
- 对季节性过敏性鼻炎患者,可考虑半剂量布地奈德联合孟鲁司特以更好改善鼻塞和降低FeNO。
- 联合治疗在减少症状未控制患者方面可能优于孟鲁司特单药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although intranasal steroids and anti-cysteinyl-leukotriene-receptor antagonists are efficacious in the treatment of seasonal allergic rhinitis (SAR), combinations of these agents have not unequivocally been demonstrated to be superior to the individual drugs. We aimed to compare the efficacy and potential mechanisms of budesonide nasal spray (BD), oral montelukast (MNT), and combination therapy comprising a half-dose of budesonide plus montelukast (hBD+MNT) in SAR patients. METHODS: We performed a single-center, randomized, open-label study in SAR subjects (n = 100). Participants were randomized to receive BD (256 μg), MNT (10 mg), or hBD (128 μg)+MNT for 14 days. Symptom severity scores, nasal cavity volume (NCV), fraction of exhaled nitric oxide (FeNO), eosinophil cationic protein (ECP), histamine and cysteinyl-leukotrienes (CysLTs), and T-cell subsets were assessed before and after treatment. RESULTS: All treatments significantly improved symptoms from baseline; however, hBD+MNT produced significantly greater improvements in nasal congestion compared with BD or MNT alone. The BD and hBD+MNT groups had fewer patients with uncontrolled symptoms and improved NCV to a greater level than the MNT group. FeNO was decreased to a significantly greater extent from baseline after hBD+MNT treatment than after BD and MNT treatments. ECP, histamine, and CysLTs showed significantly greater decreases after BD and hBD+MNT treatments than after MNT treatment. BD decreased T-helper 1 (Th1) and Th2 cells and increased T-regulatory (Treg) cells in nasal mucosa and MNT decreased Th1 cells and increased Treg cells in peripheral blood, and this trend was reflected with hBD+MNT. CONCLUSION: The hBD+MNT combination may have an overall better efficacy profile than BD and MNT monotherapy for treatment of SAR.
引用
- Chen H, Lou H, Wang Y, et al. Comparison of the efficacy and mechanisms of intranasal budesonide, montelukast, and their combination in treatment of patients with seasonal allergic rhinitis. Int Forum Allergy Rhinol. 2018. PMID: 30144304. doi:10.1002/alr.22197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。